Stem-Therapy Backing Causes Shares to Fall 14.4%
Sumitomo Pharma’s stock price dropped by as much as 14.4% on Friday after Japan approved its regenerative therapy, which is based on technology developed by a Nobel Prize winner. The approval was given conditionally, with the company required to collect more data over the next seven years. Analysts think this might be the reason for … Read more